Last fall, we asked the question on our other blogWill Invokana Injury Cases Be Centralized? At that time, a growing number of injured patients had filed lawsuits in Federal Courts. Our firm has been investigating potential Invokana injury claims for some time. For background information on the drug Invokana and its associated injuries, you can read more on the Hot Topics section of our law firm website.

Continue Reading

In September, I discussed new anticoagulants Xarelto and Eliquis. My prior post concludes by noting patients deserve drugs approved only after careful study for safety.

Shortly after that post, the ISMP Quarterwatch also raised issues concerning the safety of new anticoagulants rivaroxaban (Xarelto), dabigatron (Pradaxa), and apixaban (Eliquis). According to Quarterwatch:

The adverse event

Will Eliquis join Pradaxa and Xarelto as another anti-coagulant drug facing claims of severe internal bleeding? Pradaxa was the first of these three new anti-coagulants (blood thinners). It hit the market in 2010. Sales quickly boomed. However, adverse reports of severe internal hemorrhaging and bleeding soon followed. In May 2014, Pradaxa’s manufacturer settled about 4,000

What is Xarelto?

Xarelto (Rivaroxaban) is a relatively new anticoagulant (blood thinner). The FDA first approved Xarelto in 2011. It is distributed in the United States by Johnson & Johnson subsidiary Janssen Pharmaceuticals and Bayer Healthcare. Xarelto was released as a replacement for Coumadin (Warfarin), a blood thinner effectively used for decades.

Xarelto is used

Last week, a Federal Court jury in Florida found Boston Scientific liable for the severe personal injuries caused by one of its transvaginal mesh products. The Florida case involved four women suffering tremendous problems from implanted mesh. The jury assessed $26.7 Million in damages against the company. This was not the first trial loss